araag2/HINT huggingface dataset:
Clinical trial NCT00069459 (phase 1, status: completed)
Conditions: depressive disorder
ICD codes: F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9
Drugs: extended-release bupropion hydrochloride
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  History of Major Depressive Disorder (MDD) with a seasonal pattern.

        Exclusion Criteria:

          -  Current or past history of seizure disorder or brain injury.

          -  History or current diagnosis of anorexia nervosa or bulimia.

          -  Recurrent summer depression more frequently than winter depression.

          -  Primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD),
             Post-traumatic Stress Disorder(PTSD), acute distress disorder, bipolar II disorder or
             other psychotic disorders.

          -  Initiated psychotherapy within the last 3 months.
Clinical trial NCT01187043 (phase 1/phase 2, status: completed)
Conditions: amenorrhea
ICD codes: N91.0, N91.1, N91.2
Drugs: proellex
SMILES: [H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Ability to understand and provide a written informed consent.

          -  Healthy adult females between 18 and 50 years of age. Included in this group are women
             with the following conditions, not currently receiving drug treatment:

               -  Excessive menstrual bleeding;

               -  Menstrual pain;

               -  Confirmed uterine fibroids; and

               -  Confirmed endometriosis

          -  Normal menstrual cycle of 26-32 days

          -  Agree not to attempt to become pregnant

          -  Agree to limit alcohol consumption to no more than 2 drinks per week and to avoid
             alcohol consumption within 48 hours of each visit

          -  Ability to swallow gelatin capsules Ability to complete a daily subject diary

          -  Willing to discontinue hormonal contraceptives and consent to use of double barrier
             contraceptive techniques over the course of the study.

          -  Has a negative pregnancy test at the Screening and Baseline visits An exception for
             the pregnancy test requirement will be granted for subjects reporting surgical
             sterilization in medical history

          -  A Body Mass Index (BMI) between 18 and 39 inclusive

          -  Is available for all treatment and follow-up visits

        Exclusion Criteria:

          -  Subject is a post-menopausal woman, defined as either; six (6) months or more
             (immediately prior to screening visit) without a menstrual period, or prior
             hysterectomy and/or oophorectomy

          -  Subject is pregnant or lactating or is attempting or expecting to become pregnant
             during the 7 month study period

          -  Women with abnormal liver enzymes or liver disease.

          -  Subject previously participated in Proellex clinical trials: ZPE-201, ZPU-003,
             ZPU-301, ZPU-302, ZPU-303, ZPU-304, ZPU-305, and ZPU-307.

          -  Received an investigational drug in the 30 days prior to the screening for this study

          -  Women with a history of PCOS

          -  Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids,
             DHEA or hormonal products for at least 2 weeks prior to screening and during the
             study.

          -  Use of oral contraceptives or hormone releasing IUDs in the preceding 30 days. Use of
             Depo-Provera® in the preceding 6 months.

          -  Women currently using narcotics

          -  Women currently taking cimetidine or spironolactone

          -  Clinically significant abnormal findings on screening examination or any condition
             which in the opinion of the investigator would interfere with the participant's
             ability to comply with the study instructions or endanger the participant if she took
             part in the study
Clinical trial NCT00722488 (phase 1, status: completed)
Conditions: hematologic malignancies, multiple myeloma, lymphoma, hodgkin lymphoma
ICD codes: E70.338, E70.339, P09.3, O28.0, P61.8, P61.9, T45.8X1A, C90.01, C90.02, C90.00, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: mln4924
SMILES: [H][C@]1(O)C[C@@]([H])(C[C@@]1([H])COS(N)(=O)=O)N1C=CC2=C(N[C@@]3([H])CCC4=CC=CC=C34)N=CN=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          -  Patients must have a confirmed diagnosis of lymphoma (Waldenstrom's macroglobulinemia
             is permitted) or multiple myeloma that is relapsed and/or refractory after at least 2
             prior standard chemotherapeutic regimens and for which no curative option exists.

             1. As of Protocol Amendment 7, patients in the expansion cohort, Schedule E, must
             specifically have Hodgkin lymphoma, DLBCL-GCB subtype, DLBCL-non-GCB subtype, or
             Mantle Cell Lymphoma (MCL). Patients with multiple myeloma will no longer be evaluated
             as a part of this study.

          -  Tumor that is evaluable by radiography, serum or urine electrophoresis (for patients
             with multiple myeloma), or clinical evaluations.

             1. As of Protocol Amendment 7, tumor that is evaluable by radiography or clinical
             evaluations.

          -  Suitable venous access for the conduct of blood sampling for MLN4924

          -  Adequate Organ Function

        Exclusion Criteria:

          -  Systemic antineoplastic therapy within 21 days preceding first dose of study
             treatment, or rituximab therapy within 2 months preceding first dose of study
             treatment (unless there was evidence of PD since their last dose of rituximab).

          -  Treatment with corticosteroids within 7 days preceding first dose of study treatment.

          -  Prior treatment with radiation therapy involving >25% of bone marrow; Any radiotherapy
             within 14 days before first dose of study treatment.

          -  Treatment with CYP3A inducers within 14 days before the first dose of MLN4924.
             Moderate and strong CYP3A inhibitors and CYP3A inducers are not permitted during the
             study.

          -  Patients requiring Coumadin who cannot be switched to a low molecular weight heparin
             should not be considered for this study.

          -  Absolute neutrophil count less than 1,000/mm3; platelet count less than 75,000/mm3.

          -  Calculated creatinine clearance less than or equal to 50 mL/minute.
Clinical trial NCT00889421 (phase 1/phase 2, status: terminated)
Conditions: uveitis
ICD codes: H44.133, H44.131, H44.132, H44.139
Drugs: apremilast
SMILES: [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1
Reason stopped: 
    investigator discretion due to lack of efficacy in three subjects enrolled
  
Eligibility criteria:

        Inclusion Criteria:

          -  patients with vision-threatening autoimmune uveitis

          -  failure to respond to prednisone and at least one other systemic immunosuppressive, or
             intolerance to such medications due to side effects

        Exclusion Criteria:

          -  serious concomitant illness that could interfere with the subject's participation

          -  previous or current use of an alkylating agent

          -  use of CYP3A4 inhibitors during the trial

          -  TNF blocker use within the 8 weeks prior to enrollment
Clinical trial NCT00445315 (phase 1, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: pf-00868554, pf-00868554, pf-00868554, pf-00868554, placebo
SMILES: CCC1=CC(CC[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C2CCCC2)=CC(CC)=N1, CCC1=CC(CC[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C2CCCC2)=CC(CC)=N1, CCC1=CC(CC[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C2CCCC2)=CC(CC)=N1, CCC1=CC(CC[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C2CCCC2)=CC(CC)=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  HCV RNA ≥ 100,000 IU/mL at screening

          -  Genotype 1a or 1b

        Exclusion Criteria:

          -  Current or prior treatment with IFN and/or RBV

          -  Evidence of decompensated liver disease
Clinical trial NCT00095706 (phase 1/phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bevacizumab (drug), herceptin (drug)
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic or relapsed locally advanced breast cancer

          -  HER2-positive by FISH

          -  No prior chemotherapy for metastatic disease

          -  ECOG performance status 0-2

          -  Normal left ventricular ejection fraction

          -  Bidimensionally measurable disease

          -  Oxygen saturation > 90% on room air

        Exclusion Criteria:

          -  Other invasive malignancy within 5 years

          -  More than 3 different metastatic sites

          -  >50% liver involvement by metastasis

          -  Newly diagnosed untreated Stage IIIB breast cancer

          -  Prior chemotherapy for metastatic disease

          -  Clinically significant cardiovascular disease

          -  History or evidence of CNS disease

          -  Major surgery within 28 days prior to day 0

          -  Current or recent use of parenteral anticoagulants

          -  WBC < 3,000/uL

          -  Platelet count < 75,000/uL

          -  Hemoglobin < 9.0 g/dL

          -  Total Bilirubin > 2.0 mg/dL

          -  AST or ALT > 5 time upper limit of normal for subjects with documented liver
             metastases; > 2.5 times upper limit of normal for subjects without evidence of liver
             metastases

          -  Proteinuria (> 1g protein/24 hours at baseline)

          -  Prior therapy with Herceptin or rhuMAb VEGF (bevacizumab)
Clinical trial NCT00153881 (phase 1, status: completed)
Conditions: esophageal neoplasms
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: capecitabine (xeloda)
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Esophageal or gastroesophageal junction cancer that is locally advanced and surgically
             resectable (stage II or III disease).

          -  No prior therapy.

          -  Adequate organ function.

        Exclusion Criteria:

          -  Evidence of metastasis (celiac axis lymph nodes are allowed).

          -  Cervical esophageal tumors.

          -  Peripheral or auditory neuropathy grade >= 2.
Clinical trial NCT00116376 (phase 1/phase 2, status: completed)
Conditions: glioblastoma multiforme
ICD codes: L51.0, L51.8, L51.9
Drugs: aee788
SMILES: [H][C@](C)(N=C1N=CNC2=C1C=C(N2)C1=CC=C(CN2CCN(CC)CC2)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed GBM in first or second recurrence or relapse

          -  Adequate hematologic, hepatic and renal function

          -  Age ≥ 18 years

          -  Karnofsky performance status score ≥ 70%

          -  Life expectancy ≥ 12 weeks

        Exclusion Criteria:

          -  Peripheral neuropathy > grade 1

          -  Diarrhea > grade 1

          -  Gastrointestinal dysfunction

          -  Compromised cardiac function

          -  Concurrent severe and/or uncontrolled medical conditions
Clinical trial NCT00716417 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bibw 2992, bibw 2992
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion criteria:

          1. Patients with histologically or cytologically confirmed diagnosis of non resectable
             and / or metastatic cancer, preferably squamous cell carcinomas of head and neck,
             oesophagus, lung or cervix

          2. Indication for a standard treatment with either cisplatin plus paclitaxel or cisplatin
             plus 5 FU as judged by the investigator

          3. Age 18 years or older.

          4. Life expectancy of at least three (3) months.

          5. Written informed consent that is consistent with ICH-GCP guidelines.

          6. Eastern Cooperative Oncology Group (ECOG) performance score less or equal 2.

          7. Patients must have recovered from any therapy-related toxicity from previous chemo-,
             hormone-, immuno-, or radiotherapies.

          8. Patients recovered from previous surgery.

        Exclusion criteria:

          1. Active infectious disease.

          2. Gastrointestinal disorders that may interfere with the absorption of the study drug or
             chronic diarrhoea.

          3. Serious illness or concomitant non-oncological disease considered by the investigator
             to be incompatible with the protocol.

          4. Patients with untreated or symptomatic brain metastases. Patients with treated,
             asymptomatic brain metastases are eligible if there has been no change in brain
             disease status for at least four (4) weeks, no history of cerebral oedema or bleeding
             in the past four (4) weeks and no requirement for steroids or anti-epileptic therapy.

          5. Cardiac left ventricular function with resting ejection fraction less than 50%

          6. Absolute neutrophil count (ANC) less than 1500 / mm3.

          7. Platelets count less than 100 000/mm3.

          8. Bilirubin more than 1.5 x upper limit of institutional norm.

          9. Aspartate amino transferase (AST) or alanine amino transferase (ALT) more than 3 x
             upper limit of institutional norm.

         10. Serum creatinine more than 1.5 x upper limit of institutional norm.

         11. Women and men sexually active and unwilling to use a medically acceptable method of
             contraception.

         12. Pregnancy or breast-feeding.

         13. Treatment with other investigational drugs; chemotherapy, immunotherapy, or
             radiotherapy or participation in another clinical study with anti-cancer therapy
             within the past 4 weeks before start of therapy or concomitantly with this study.

         14. Treatment with an EGFR- or HER2 inhibiting drug within the past four weeks before
             start of therapy or concomitantly with this study (2 weeks for trastuzumab).

         15. Patients unable to comply with the protocol.

         16. Active alcohol or drug abuse.
Clinical trial NCT00113919 (phase 1/phase 2, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: busulfan
SMILES: CS(=O)(=O)OCCCCOS(C)(=O)=O
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have symptomatic multiple myeloma requiring treatment

          -  Patients must have been approved for single or tandem autologous transplant

          -  Patients must be > or = 65 years of age or diagnosed with renal insufficiency, defined
             as having a creatinine > 3 mg/dl or a creatinine clearance < 30 ml/minute

          -  Patients must not have a history of chronic obstructive or chronic restrictive
             pulmonary disease. Patients must have adequate pulmonary function studies > 50% of
             predicted on mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) > 50%
             of predicted,

          -  Patients must have an ECHO or MUGA performed within 60 days prior to registration,
             LVEF > 40%.

          -  Bilirubin, SGOT, SGPT must be less than 1.5 times the upper limit of normal

          -  Patients must have evaluable myeloma marker for response such as: *Serum M protein
             >1g/dl or urine M protein >1g/24 hours and/or; *Bone marrow plasmacytosis with >20%
             plasma cells and/or; *Extramedullary plasmacytosis; *MRI/PET scan has focal lesions
             due to myeloma.

          -  Patients must be able to receive full doses of DT-PACE, in the opinion of the treating
             investigator, with the exception of cisplatin.

          -  Patients must have a performance status of 0-2 based on SWOG criteria unless the
             patient's status is due to active myeloma

          -  All patients must be informed of the investigational nature of the study and have
             signed an IRB-approved informed consent in accordance with institutional and federal
             guidelines.

        Exclusion Criteria:

          -  Serum transaminases > 1.5 x ULN and direct bilirubin > 1.5 mg/dl

          -  HIV positive or active Hepatitis B or Hepatitis C infection; (if serology is positive
             a quantitative PCR will be done).

          -  Patients with a prior malignancy in whom life expectancy is more likely to be
             determined by the prior malignancy than the myeloma. Patients must not currently be
             receiving therapy for the prior malignancy.

          -  Pregnant or nursing women. Women of childbearing potential must have a negative
             pregnancy test documented within one week of registration. Women/men of reproductive
             potential may not participate unless they have agreed to use an effective
             contraceptive method.
Clinical trial NCT01518257 (phase 1/phase 2, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: normal saline
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Painful osteoarthritis in the study knee

          -  Able to walk without assistive walking devices, able to perform usual daily
             activities, and agree to maintain similar activity level throughout the study

        Exclusion Criteria:

          -  Chronic pain conditions other than knee osteoarthritis

          -  Presence of bursitis, meniscus tear, ligament tear, or significant injury to the study
             knee within 1 year

          -  Surgery to the study knee within 24 weeks

          -  Treatment with hyaluronic acid in the study knee within 24 weeks

          -  Treatment with corticosteroids in the study knee within 12 weeks

          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral
             sclerosis

          -  Previous treatment with botulinum toxin of any serotype for any reason
Clinical trial NCT01511302 (phase 1, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: rns60, normal saline, budesonide
SMILES: O, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female non-smokers, aged between 18 and 65 years.

          -  Clinical diagnosis of mild to moderate asthma meeting NHLBI 2007 guidelines as
             outlined in Appendix A.

          -  Subjects who have a currently prescribed inhaled corticosteroid medication to treat
             asthma, alone or in combination with other medications, with usage of 1 month (≥ 95%
             compliance) or more on the inhaled corticosteroid treatment.

          -  Normal 12-lead ECG at Screening.

          -  Normal single view chest x-ray at Screening.

          -  Men and women of reproductive potential who commit to use adequate contraception
             during the study and for 1 month following the last day of treatment (Day 57).

          -  Women of childbearing potential who have a negative pregnancy test (serum HCG) at the
             time of study entry, and again on Day 22.

          -  Subjects, or their legal guardians, must be capable of understanding the purpose and
             risks of the study and provide written, voluntary, informed consent.

        Exclusion Criteria:

          -  Chronic or acute disease that might interfere with the evaluation of RNS60.

          -  Pregnancy, intent to become pregnant, or breastfeeding.

          -  Current or prior malignancies (excluding non-melanoma skin carcinoma or in situ
             carcinoma of the cervix that has been adequately treated).

          -  Positive viral serology test for Human Immunodeficiency Virus (HIV-1), HBsAG and
             Hepatitis C antibody.

          -  Positive urine drug screen (UDS) for drugs of abuse including alcohol and cotinine at
             the time of study entry and again on Day 22.

          -  Infections that require intravenous antibiotic therapy.

          -  Significant organ dysfunction, including cardiac, renal, liver, central nervous
             system, pulmonary, vascular, gastrointestinal, endocrine, or metabolic (e.g.,
             creatinine ≥ 1.6 mg/dL; ALT or AST ≥ 1.5x the upper limit of normal), history of
             myocardial infarction, congestive heart failure, or arrhythmias within 6 months prior
             to study entry.

          -  Treatment with a humanized or chimeric antibody therapy within 4 weeks prior to study
             entry.

          -  Treatment with any investigational drugs, therapies, or medical devices within 4 weeks
             prior to study entry.

          -  Any use of antidepressants or other psychiatric medicine within 4 weeks prior to study
             entry and/or during the study treatment period.

          -  Use of any over-the-counter asthma treatments, including Primatene Mist, during the
             8-week active study period.
Clinical trial NCT01123785 (phase 1/phase 2, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: ino-8875, placebo
SMILES: O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)N1C=NC2=C(NC3CCCC3)N=CN=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Subject has the diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma
             (POAG).

          2. Aged 18 to 75 years.

          3. Mean intraocular pressure (IOP) of ≥24 and ≤34 mm Hg.

        Exclusion Criteria:

          1. No significant visual field loss or any new field loss within the past year.

          2. Cup-to-disc ratio ≥0.8

          3. Central corneal thickness <500 µm or >600 µm

          4. History of adult asthma or chronic obstructive pulmonary disease

          5. A recent (acute) or chronic medical condition that might obfuscate the Subject's study
             data
Clinical trial NCT00568022 (phase 1, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ixabepilone, capecitabine
SMILES: [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Women ≥ 20 years

          -  Histologically or cytologically confirmed diagnosis of adenocarcinoma originating in
             the breast

        Exclusion Criteria:

          -  Number of prior chemotherapy lines of treatment in the metastatic setting ≥3